Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 347

1.

Frequent methylation of the tumour suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification.

Wang LQ, Kumar S, Calin GA, Li Z, Chim CS.

Br J Haematol. 2020 Feb 20. doi: 10.1111/bjh.16517. [Epub ahead of print]

PMID:
32079038
2.

Loss of p53 drives neuron reprogramming in head and neck cancer.

Amit M, Takahashi H, Dragomir MP, Lindemann A, Gleber-Netto FO, Pickering CR, Anfossi S, Osman AA, Cai Y, Wang R, Knutsen E, Shimizu M, Ivan C, Rao X, Wang J, Silverman DA, Tam S, Zhao M, Caulin C, Zinger A, Tasciotti E, Dougherty PM, El-Naggar A, Calin GA, Myers JN.

Nature. 2020 Feb;578(7795):449-454. doi: 10.1038/s41586-020-1996-3. Epub 2020 Feb 12.

PMID:
32051587
3.

When non-coding is not enough.

Anfossi S, Calin GA.

J Exp Med. 2020 Mar 2;217(3). pii: e20192009. doi: 10.1084/jem.20192009.

PMID:
32023341
4.

Long non-coding RNA uc.291 controls epithelial differentiation by interfering with the ACTL6A/BAF complex.

Panatta E, Lena AM, Mancini M, Smirnov A, Marini A, Delli Ponti R, Botta-Orfila T, Tartaglia GG, Mauriello A, Zhang X, Calin GA, Melino G, Candi E.

EMBO Rep. 2020 Feb 4:e46734. doi: 10.15252/embr.201846734. [Epub ahead of print]

5.

Corrigendum to 'Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer' [EBioMedicine 38 (2018) 100-112].

Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G.

EBioMedicine. 2020 Jan 20;52:102630. doi: 10.1016/j.ebiom.2020.102630. [Epub ahead of print] No abstract available.

6.

miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.

Fuentes-Mattei E, Bayraktar R, Manshouri T, Silva AM, Ivan C, Gulei D, Fabris L, Soares do Amaral N, Mur P, Perez C, Torres-Claudio E, Dragomir MP, Badillo-Perez A, Knutsen E, Narayanan P, Golfman L, Shimizu M, Zhang X, Zhao W, Ho WT, Estecio MR, Bartholomeusz G, Tomuleasa C, Berindan-Neagoe I, Zweidler-McKay PA, Estrov Z, Zhao ZJ, Verstovsek S, Calin GA, Redis RS.

JCI Insight. 2020 Jan 16;5(1). pii: 121781. doi: 10.1172/jci.insight.121781.

7.

GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.

El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G.

Cell Signal. 2020 Jan 11;68:109539. doi: 10.1016/j.cellsig.2020.109539. [Epub ahead of print]

8.

The role of exosomal long non-coding RNAs in cancer drug resistance.

De Los Santos MC, Dragomir MP, Calin GA.

Cancer Drug Resist. 2019 Dec 19;2:1178-1192. doi: 10.20517/cdr.2019.74.

9.

Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum.

Oncul S, Amero P, Rodriguez-Aguayo C, Calin GA, Sood AK, Lopez-Berestein G.

RNA Biol. 2019 Dec 17:1-12. doi: 10.1080/15476286.2019.1702283. [Epub ahead of print]

PMID:
31847695
10.

Non-Coding RNAs in IGF-1R Signaling Regulation: The Underlying Pathophysiological Link between Diabetes and Cancer.

Chen B, Li J, Chi D, Sahnoune I, Calin S, Girnita L, Calin GA.

Cells. 2019 Dec 14;8(12). pii: E1638. doi: 10.3390/cells8121638. Review.

11.

Therapeutic Potential of the miRNA-ATM Axis in the Management of Tumor Radioresistance.

Rezaeian AH, Khanbabaei H, Calin GA.

Cancer Res. 2020 Jan 15;80(2):139-150. doi: 10.1158/0008-5472.CAN-19-1807. Epub 2019 Nov 25. Review.

PMID:
31767626
12.

Molecular aspects of medicine - Editorial 2019.

Calin GA, Fabris L.

Mol Aspects Med. 2019 Dec;70:1-2. doi: 10.1016/j.mam.2019.11.003. Epub 2019 Nov 14. No abstract available.

PMID:
31735351
13.

Long Non-coding RNAs in Myeloid Malignancies.

Zimta AA, Tomuleasa C, Sahnoune I, Calin GA, Berindan-Neagoe I.

Front Oncol. 2019 Oct 18;9:1048. doi: 10.3389/fonc.2019.01048. eCollection 2019. Review.

14.

Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma.

Barth DA, Slaby O, Klec C, Juracek J, Drula R, Calin GA, Pichler M.

Cancers (Basel). 2019 Oct 17;11(10). pii: E1580. doi: 10.3390/cancers11101580. Review.

15.

A multiscale agent-based model of ductal carcinoma in situ.

Butner JD, Fuentes D, Ozpolat B, Calin GA, Zhou X, Lowengrub J, Cristini V, Wang Z.

IEEE Trans Biomed Eng. 2019 Oct 8. doi: 10.1109/TBME.2019.2938485. [Epub ahead of print]

PMID:
31603768
16.

Below the Surface: IGF-1R Therapeutic Targeting and Its Endocytic Journey.

Crudden C, Song D, Cismas S, Trocmé E, Pasca S, Calin GA, Girnita A, Girnita L.

Cells. 2019 Oct 9;8(10). pii: E1223. doi: 10.3390/cells8101223. Review.

17.

MiR-200 family and cancer: From a meta-analysis view.

Huang GL, Sun J, Lu Y, Liu Y, Cao H, Zhang H, Calin GA.

Mol Aspects Med. 2019 Dec;70:57-71. doi: 10.1016/j.mam.2019.09.005. Epub 2019 Sep 23. Review.

PMID:
31558294
18.

The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database.

Li Y, Chen M, Pardini B, Dragomir MP, Lucci A, Calin GA.

J Transl Med. 2019 Sep 23;17(1):318. doi: 10.1186/s12967-019-2069-y.

19.

GLS2 is protumorigenic in breast cancers.

Dias MM, Adamoski D, Dos Reis LM, Ascenção CFR, de Oliveira KRS, Mafra ACP, da Silva Bastos AC, Quintero M, de G Cassago C, Ferreira IM, Fidelis CHV, Rocco SA, Bajgelman MC, Stine Z, Berindan-Neagoe I, Calin GA, Ambrosio ALB, Dias SMG.

Oncogene. 2020 Jan;39(3):690-702. doi: 10.1038/s41388-019-1007-z. Epub 2019 Sep 20.

PMID:
31541193
20.

The non-coding RNome after splenectomy.

Dragomir MP, Tudor S, Okubo K, Shimizu M, Chen M, Giza DE, He WR, Ivan C, Calin GA, Vasilescu C.

J Cell Mol Med. 2019 Nov;23(11):7844-7858. doi: 10.1111/jcmm.14664. Epub 2019 Sep 8.

Supplemental Content

Loading ...
Support Center